Preclinical alterations in cardiac energetics amongst sarcomere mutation carriers in hypertrophic cardiomyopathy
نویسندگان
چکیده
Background Hypertrophic cardiomyopathy (HCM) is characterised by reduced myocardial tissue oxygenation (assessed using blood oxygen level dependent (BOLD) CMR imaging) during stress, as well as reduced myocardial perfusion reserve (MPRI) due to coronary microvascular dysfunction. In HCM gene carriers without the HCM phenotype, it has been suggested that only oxygenation is impaired. [1] It remains unclear whether this relates to early cardiac remodelling/ diastolic dysfunction, or whether oxygen consumption is intrinsically altered with sarcomere mutations. We sought to assess the BOLD signal change during vasodilator stress in a homogenous group of MYPBC3 positive HCM patients (some with clinical HCM, and some with no phenotypic features of HCM), and normal controls.
منابع مشابه
ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study)
INTRODUCTION Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease mostly due to mutations in genes encoding sarcomeric proteins. HCM is characterised by asymmetric hypertrophy of the left ventricle (LV) in the absence of another cardiac or systemic disease. At present it lacks specific treatment to prevent or reverse cardiac dysfunction and hypertrophy in mutation carriers a...
متن کاملApical Hypertrophic Cardiomyopathy in a Case with Chest Pain and Family History of Sudden Cardiac Death: A Case Report
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, which is caused by a multitude of mutations in genes encoding proteins of the cardiac sarcomere (1). Apical hypertrophic cardiomyopathy (AHCM) is an uncommon type of HCM. The sudden cardiac death is less likely to occur in the patients inflicted with AHCM (2). Herein, we presented the case of a 29-year-old man ...
متن کاملLeft Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy
BACKGROUND Impaired left atrial (LA) function is an early marker of cardiac dysfunction and predictor of adverse cardiac events. Herein, we assess LA structure and function in hypertrophy in hypertrophic cardiomyopathy (HCM) sarcomere mutation carriers with and without left ventricular hypertrophy (LVH). METHOD Seventy-three participants of the HCMNet study who underwent cardiovascular magnet...
متن کاملDerangement of cardiac energy metabolism is acutely exacerbated during exercise in hypertrophic cardiomyopathy, independent of hypertrophy or late gadolinium burden
Background In hypertrophic cardiomyopathy (HCM), sarcomere mutations increase the energy cost of contraction. Impaired resting cardiac energetics as measured by phosphocreatine/adenosine triphosphate (PCr/ATP) using 31Phosphorus MR Spectroscopy(31P MRS) has been documented in animal models and patients. We hypothesize that: 1.Cardiac energetics are further impaired acutely during exercise in HC...
متن کاملDiltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
OBJECTIVES The study sought to assess the safety, feasibility, and effect of diltiazem as disease-modifying therapy for at-risk hypertrophic cardiomyopathy (HCM) mutation carriers. BACKGROUND HCM is caused by sarcomere mutations and characterized by left ventricular hypertrophy (LVH) with increased risk of heart failure and sudden death. HCM typically cannot be diagnosed early in life, althou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 17 شماره
صفحات -
تاریخ انتشار 2015